Sight
Sight develops technology to decode live immune cells in action using proprietary data and artificial intelligence. The company focuses on creating a new generation of immune signatures to provide clinical insights. Its work centers on the intersection of machine vision and immunology to improve diagnostic outcomes.
Healthtech
Biotechnology
Artificial Intelligence
Diagnostics
Funding summary
- Total raised
- €60.3M
- Funding rounds
- 1
Investors in Sight
Investors on record for Sight. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Sight?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors